Ali Sovari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ali Sovari has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Leili Pourafkari
Department of Cardiovascular Disease, Los Robles Regional Medical Center, Thousand Oaks, California; Department of Anesthesiology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York
5 shared publicationsJeong Hwan Kim
Cabrillo Cardiology Medical Group, Camarillo, California; Department of Cardiology, St. John's Regional Medical Center, Oxnard, California
3 shared publicationsJeong Hwan J. Kim
Department of Cardiovascular Disease, Los Robles Regional Medical Center, Thousand Oaks, California
2 shared publicationsJonathan Lalezari
Department of Cardiovascular Disease, Los Robles Regional Medical Center, Thousand Oaks, California
2 shared publications
Latest Publications
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Right Internal Jugular Implantation of the AVEIR Leadless Pacemaker: A Case Series Demonstrating Feasibility and Safety
Leadless pacemakers provide an alternative to transvenous pacing in patients at risk for lead- and pocket-related complications. While the femoral vein is the standard route of implantation, certain anatomical or clinical factors may make this approach technically challenging. The objective of this study was to evaluate the feasibility and safety of AVEIR (Abbott) implantation through the right internal jugular (RIJ) vein in patients in whom the femoral approach was not feasible. The authors report a single-center case series of patients who underwent AVEIR implantation using the RIJ vein. Procedural techniques, periprocedural management, and early clinical outcomes were reviewed. Eight patients (8 VR and 1 DR) underwent successful implantation through the RIJ approach. Device deployment was accomplished with stable electrical parameters and without acute complications. This case series demonstrates that AVEIR implantation via the RIJ is both technically feasible and safe. These findings expand access strategies for leadless pacing and may provide a foundation for future applications of conduction system pacing using superior venous routes.
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Right Internal Jugular Implantation of the AVEIR Leadless Pacemaker: A Case Series Demonstrating Feasibility and Safety
Leadless pacemakers provide an alternative to transvenous pacing in patients at risk for lead- and pocket-related complications. While the femoral vein is the standard route of implantation, certain anatomical or clinical factors may make this approach technically challenging. The objective of this study was to evaluate the feasibility and safety of AVEIR (Abbott) implantation through the right internal jugular (RIJ) vein in patients in whom the femoral approach was not feasible. The authors report a single-center case series of patients who underwent AVEIR implantation using the RIJ vein. Procedural techniques, periprocedural management, and early clinical outcomes were reviewed. Eight patients (8 VR and 1 DR) underwent successful implantation through the RIJ approach. Device deployment was accomplished with stable electrical parameters and without acute complications. This case series demonstrates that AVEIR implantation via the RIJ is both technically feasible and safe. These findings expand access strategies for leadless pacing and may provide a foundation for future applications of conduction system pacing using superior venous routes.
- Open Access
- 15 February 2016
- Published by Wiley in Cardiology Research and Practice
- Vol. 2016, 1-7
Cellular and Molecular Mechanisms of Arrhythmia by Oxidative Stress
Current therapies for arrhythmia using ion channel blockade, catheter ablation, or an implantable cardioverter defibrillator have limitations, and it is important to search for new antiarrhythmic therapeutic targets. Both atrial fibrillation and heart failure, a condition with increased arrhythmic risk, are associated with excess amount of reactive oxygen species (ROS). There are several possible ways for ROS to induce arrhythmia. ROS can cause focal activity and reentry. ROS alter multiple cardiac ionic currents. ROS promote cardiac fibrosis and impair gap junction function, resulting in reduced myocyte coupling and facilitation of reentry. In order to design effective antioxidant drugs for treatment of arrhythmia, it is essential to explore the molecular mechanisms by which ROS exert these arrhythmic effects. Activation of Ca2+/CaM-dependent kinase II, c-Src tyrosine kinase, protein kinase C, and abnormal splicing of cardiac sodium channels are among the recently discovered molecular mechanisms of ROS-induced arrhythmia.
- 15 February 2016
- Published by Wiley in Cardiology Research and Practice
- Vol. 2016, 1-7
Open AccessCellular and Molecular Mechanisms of Arrhythmia by Oxidative Stress
Current therapies for arrhythmia using ion channel blockade, catheter ablation, or an implantable cardioverter defibrillator have limitations, and it is important to search for new antiarrhythmic therapeutic targets. Both atrial fibrillation and heart failure, a condition with increased arrhythmic risk, are associated with excess amount of reactive oxygen species (ROS). There are several possible ways for ROS to induce arrhythmia. ROS can cause focal activity and reentry. ROS alter multiple cardiac ionic currents. ROS promote cardiac fibrosis and impair gap junction function, resulting in reduced myocyte coupling and facilitation of reentry. In order to design effective antioxidant drugs for treatment of arrhythmia, it is essential to explore the molecular mechanisms by which ROS exert these arrhythmic effects. Activation of Ca2+/CaM-dependent kinase II, c-Src tyrosine kinase, protein kinase C, and abnormal splicing of cardiac sodium channels are among the recently discovered molecular mechanisms of ROS-induced arrhythmia.
- Open Access
- 1 January 2011
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2011, 1-2
Antioxidant Therapy for Atrial Fibrillation: What Is the Next Step?
- 1 January 2011
- Published by Hindawi Limited in Cardiology Research and Practice
- Vol. 2011, 1-2
Open AccessAntioxidant Therapy for Atrial Fibrillation: What Is the Next Step?
- Open Access
- Vol. 17 (6) , 6754-6757
Right Ventricular Implantation of an Aveir™ AR Device for Bradycardia in a 90-Year-Old Woman with Atrial Fibrillation and Small Right Ventricular Dimensions
We report a case of implanting an Aveir™ AR (atrial) leadless pacemaker (Abbott, Chicago, IL, USA) in the right ventricle (RV) of a 90-year-old woman with permanent atrial fibrillation with pauses. The patient initially received an Aveir™ VR (ventricular) device for rate support. During implantation, elevated pacing thresholds and tricuspid valve (TV) interaction were noted, which improved with repositioning. The patient subsequently presented with recurrent loss of capture secondary to elevated thresholds. Device interrogation and imaging suggested that the Aveir™ VR device was suboptimal due to the patient’s small RV cavity and interaction with TV. To address this, the pacemaker was extracted, and an Aveir™ AR device—featuring a smaller profile—was successfully implanted in the RV, achieving stable fixation. To the best of our knowledge, this is the first reported case of off-label RV implantation of an Aveir™ AR device. This case illustrates the versatility of modular leadless pacing systems and underscores the importance of tailoring device selection to individual cardiac anatomy, particularly TV, in elderly patients with small RV dimensions.
- Vol. 17 (6) , 6754-6757
Open AccessRight Ventricular Implantation of an Aveir™ AR Device for Bradycardia in a 90-Year-Old Woman with Atrial Fibrillation and Small Right Ventricular Dimensions
We report a case of implanting an Aveir™ AR (atrial) leadless pacemaker (Abbott, Chicago, IL, USA) in the right ventricle (RV) of a 90-year-old woman with permanent atrial fibrillation with pauses. The patient initially received an Aveir™ VR (ventricular) device for rate support. During implantation, elevated pacing thresholds and tricuspid valve (TV) interaction were noted, which improved with repositioning. The patient subsequently presented with recurrent loss of capture secondary to elevated thresholds. Device interrogation and imaging suggested that the Aveir™ VR device was suboptimal due to the patient’s small RV cavity and interaction with TV. To address this, the pacemaker was extracted, and an Aveir™ AR device—featuring a smaller profile—was successfully implanted in the RV, achieving stable fixation. To the best of our knowledge, this is the first reported case of off-label RV implantation of an Aveir™ AR device. This case illustrates the versatility of modular leadless pacing systems and underscores the importance of tailoring device selection to individual cardiac anatomy, particularly TV, in elderly patients with small RV dimensions.